Noticias y Actividades de Teva Pharmaceutical Industries

Teva Pharmaceutical Industries es una de las ...

• Forbes Global 2000 (#935);
• TOB Iconic 10,000.

Teva Pharmaceutical Industries es una empresa que cotiza bajo el símbolo de cotización TEVA (IL).

Teva Pharmaceutical Industries tiene presencia directa en 18 países.

Teva Pharmaceutical Industries posee 19 subsidiarias incluyendo Medis Germany, Pliva y Teva ANZ.

Ver el organigrama con sus 121 ejecutivos principales

Biografías más buscadas en Teva Pharmaceutical Industries

• Richard Francis, Director, President and Chief Executive Officer
• Perry Nisen, Director
• Tal Zaks, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries tiene 1.837 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacia

• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (publicado el 16 de junio de 2025).
• Juvenescence acaba de anunciar una recaudación de fondos de 76 millones de dólares. (publicado el 22 de mayo de 2025).
• Kincell Bio acaba de anunciar una recaudación de fondos de 22 millones de dólares. (publicado el 22 de mayo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Amanda Moore - Vice President, Program Leadership and Clinical Operations en Abeona Therapeutics
• Jean-Michel Demeure - Vice President, Finance Global Operations en Sanofi

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Teva Pharmaceutical Industries

• Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
• Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
• Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
• Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
• Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
• Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
• Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
• Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
• Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
• Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
• View more press releases Close

Redes sociales sobre Teva Pharmaceutical Industries

• Teva Pharmaceutical Industries en Wikipedia, Google News y Yahoo Finance
• Teva Pharmaceutical Industries en LinkedIn, Twitter y YouTube